<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3195">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04537962</url>
  </required_header>
  <id_info>
    <org_study_id>4172-20</org_study_id>
    <nct_id>NCT04537962</nct_id>
  </id_info>
  <brief_title>Evaluationof the Load of SARS-CoV-2 Virus in Oral Cavity, Oropharinge and Saliva of Patients With Covid-19 After Disinfection With Oral Antimicrobial Solutions: a Pilot Study</brief_title>
  <official_title>Avaliação do Covid-19 na Cavidade Oral, Orofaringe e Saliva após desinfecção Com soluções Antimicrobianas Orais: Estudo Piloto.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Israelita Albert Einstein</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Colgate Palmolive</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital Israelita Albert Einstein</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to analyze oral disinfection with 1.5% hydrogen peroxide, 0.12%
      chlorhexidine gluconate or 0.075% cetylpyridinium chloride to 0.28% zinc lactate to reduce
      the SARS-CoV viral load -2 in the oral and oropharyngeal mucosa and saliva. Patients of both
      sexes, aged between 18 and 90 years, positive for SARS-CoV-2 by the RT-PCR method and who
      require oral hygiene care and other preventive and therapeutic dental procedures that are
      used in the randomized clinical study. The study comprises two arms: Arm 1 - patients
      hospitalized in the ICU bed with orotracheal intubation - undergo disinfection of the oral
      mucosa with 1.5% hydrogen peroxide solution, after the 0.12% non-alcoholic chlorhexidine
      solution ( Peroxide and Chlorhexidine Group) or only disinfection of the oral mucosa with
      0.12% non-alcoholic chlorhexidine solution (Chlorhexidine Group - control); Arm 2 - patients
      hospitalized in the common bed without mechanical ventilation - will undergo oral
      disinfection or with 1.5% hydrogen peroxide solution (Peroxide Group), or with 0.12%
      chlorhexidine gluconate (Chlorhexidine Group) or with chloride 0.075% cetylpyridinium with
      0.28% zinc lactate (Cetylpyridinium Group) or distilled water (Placebo Group). For the
      monitoring of viral load, the following procedures are performed: Arm 1 - a scrape with swab
      on the tongue, deep groove, oral soil, performed before the first oral disinfection (T0),
      after disinfection with hydrogen peroxide (T1) , after disinfection with chlorhexidine (T2)
      and 30 minutes after the last disinfection (T3); swab of the fluid adhered to the tube,
      before disinfecting the tube with hydrogen peroxide and chlorhexidine and immediately after
      this disinfection. Arm 2 - swab in oropharynx and saliva before application of solutions
      (T0), 30 min (T1) and 2 hours after application of solutions (T2). The quantification of
      SARS-CoV-2 will be done through the polymerase chain reaction with reverse-quantitative
      transcription (RT-qPCR). If some of these solutions are effective in reducing viral load in
      the oral cavity, this result may contribute to reduce the contamination of the environment
      caused by aerosols that require dental procedures, contributing to the improvement of
      biosafety protocols against SARS-CoV-2.
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">June 11, 2020</start_date>
  <completion_date type="Anticipated">August 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Viral load of SARS-CoV-2 in the oral mucosa, oropharynx and saliva of hospitalized patients already considered positive for the virus</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Corona Virus Infection</condition>
  <arm_group>
    <arm_group_label>Colgate Periogard and Peroxyl® - ICU patients</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arm 1 - patients hospitalized in the ICU with orotracheal intubation - undergo disinfection of the oral mucosa with 1.5% hydrogen peroxide solution, following by a 0.12% non-alcoholic chlorhexidine solution ( Peroxide and Chlorhexidine Group)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Colgate Periogard® - ICU patients</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arm 1 - patients hospitalized in the ICU with orotracheal intubation - undergo disinfection of the oral mucosa with 0.12% non-alcoholic chlorhexidine solution (Chlorhexidine Group);</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Colgate Peroxyl®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arm 2 - patients hospitalized in common rooms without mechanical ventilation - will be divided into the following groups: mouthwash with 1.5% hydrogen peroxide solution (Peroxide Group)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Colgate Periogard®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arm 2 - patients hospitalized in common rooms without mechanical ventilation - will be divided into the following groups: mouthwash with 0.12% chlorhexidine gluconate (Chlorhexidine Group)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Colgate Peroxyl® and Periogard®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arm 2 - patients hospitalized in common rooms without mechanical ventilation - will be divided into the following groups: mouthwash with 1.5% hydrogen peroxide solution (Peroxide Group); mouthwash with 0.12% chlorhexidine gluconate (Chlorhexidine Group); mouthwash with 1.5% hydrogen peroxide followed by mouthwash of 0.12% non-alcoholic decorexidine solution (Peroxide and Chlorhexidine Group)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Colgate Total® Mouthwash</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arm 2 - patients hospitalized in common rooms without mechanical ventilation - will be divided into the following groups: mouthwash with 0.075% cetylpyridinium chloride associated with 0.28% zinc lactate (Cetylpyridinium Group).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Arm 2 - patients hospitalized in common rooms without mechanical ventilation - will be divided into the following groups: mouthwash with distilled water (Placebo Group).</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Colgate periogard mouthwash</intervention_name>
    <description>Patients will be submitted to disinfection of the oral mucosa with the respective solution</description>
    <arm_group_label>Colgate Periogard and Peroxyl® - ICU patients</arm_group_label>
    <arm_group_label>Colgate Periogard®</arm_group_label>
    <arm_group_label>Colgate Periogard® - ICU patients</arm_group_label>
    <arm_group_label>Colgate Peroxyl® and Periogard®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Colgate Peroxyl mouthwash</intervention_name>
    <description>Patients will be submitted to disinfection of the oral mucosa with the respective solution</description>
    <arm_group_label>Colgate Periogard and Peroxyl® - ICU patients</arm_group_label>
    <arm_group_label>Colgate Peroxyl®</arm_group_label>
    <arm_group_label>Colgate Peroxyl® and Periogard®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Colgate Total mouthwash</intervention_name>
    <description>Patients will be submitted to disinfection of the oral mucosa with the respective solution</description>
    <arm_group_label>Colgate Total® Mouthwash</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo mouthwash (water)</intervention_name>
    <description>Patients will be submitted to disinfection of the oral mucosa with the respective solution</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients positive for SARS-CoV-2 using the RT-PCR method and requiring oral hygiene
             care and other preventive and therapeutic dental procedures.

        Exclusion Criteria:

          -  Pediatric patients, negative for SARS-CoV-2 by the RT-PCR method, exhibiting oral
             ulcerations and other erosive lesions in the oral mucosa that contraindicate the use
             of hydrogen peroxide, chlorhexidine and cetylpyridinium, patients who present bleeding
             in the oral cavity. that prevents the collection of samples, patients who report a
             history of allergy, irritations or other side effects derived from the use of these
             substances, who do not adhere to the oral care protocols or those in which it is not
             possible to perform these procedures.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luciana Correa, PhD</last_name>
    <role>Study Director</role>
    <affiliation>University of Sao Paulo</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Debora H Douek, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Israelita Albert Einstein</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital israelita Albert Einstein</name>
      <address>
        <city>Sao Paulo</city>
        <zip>05652-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>July 14, 2020</study_first_submitted>
  <study_first_submitted_qc>September 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 3, 2020</study_first_posted>
  <last_update_submitted>September 2, 2020</last_update_submitted>
  <last_update_submitted_qc>September 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Listerine</mesh_term>
    <mesh_term>Cetylpyridinium</mesh_term>
    <mesh_term>Sodium Fluoride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

